These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 35141702)

  • 1. Analysis of Key Factors of a SARS-CoV-2 Vaccination Program: A Mathematical Modeling Approach.
    Martínez-Rodríguez D; Gonzalez-Parra G; Villanueva RJ
    Epidemiologia (Basel); 2021 Jun; 2(2):140-161. PubMed ID: 35141702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Delayed Vaccination Regimens: A Mathematical Modeling Approach.
    Gonzalez-Parra G
    Epidemiologia (Basel); 2021 Sep; 2(3):271-293. PubMed ID: 35118438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of age structure and vaccine prioritization on COVID-19 in West Africa.
    Taboe HB; Asare-Baah M; Yesmin A; Ngonghala CN
    Infect Dis Model; 2022 Dec; 7(4):709-727. PubMed ID: 36097593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated Number of COVID-19 Infections, Hospitalizations, and Deaths Prevented Among Vaccinated Persons in the US, December 2020 to September 2021.
    Steele MK; Couture A; Reed C; Iuliano D; Whitaker M; Fast H; Hall AJ; MacNeil A; Cadwell B; Marks KJ; Silk BJ
    JAMA Netw Open; 2022 Jul; 5(7):e2220385. PubMed ID: 35793085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the Impact of Vaccination on the Dynamics of COVID-19 in Africa: A Mathematical Modeling Study.
    Montcho Y; Nalwanga R; Azokpota P; Doumatè JT; Lokonon BE; Salako VK; Wolkewitz M; Glèlè Kakaï R
    Vaccines (Basel); 2023 Apr; 11(4):. PubMed ID: 37112769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling the impact of delaying vaccination against SARS-CoV-2 assuming unlimited vaccine supply.
    Amaku M; Covas DT; Coutinho FAB; Azevedo RS; Massad E
    Theor Biol Med Model; 2021 Jul; 18(1):14. PubMed ID: 34325717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of mild and asymptomatic infections on COVID-19 vaccines performance: A modeling study.
    Aguiar M; Van-Dierdonck JB; Mar J; Stollenwerk N
    J Adv Res; 2022 Jul; 39():157-166. PubMed ID: 35777906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of COVID-19 vaccination in the US: Averted burden of SARS-COV-2-related cases, hospitalizations and deaths.
    Yamana TK; Galanti M; Pei S; Di Fusco M; Angulo FJ; Moran MM; Khan F; Swerdlow DL; Shaman J
    PLoS One; 2023; 18(4):e0275699. PubMed ID: 37098043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants.
    Chatterjee B; Thakur SS
    Expert Rev Vaccines; 2022 Jan; 21(1):47-67. PubMed ID: 34697980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.
    Yang W; Shaman J
    medRxiv; 2021 Nov; ():. PubMed ID: 34845460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 vaccinations and rates of infections, hospitalizations, ICU admissions, and deaths in Europe during SARS-CoV-2 Omicron wave in the first quarter of 2022.
    Rzymski P; Kasianchuk N; Sikora D; Poniedziałek B
    J Med Virol; 2023 Jan; 95(1):e28131. PubMed ID: 36068643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical assessment of the impact of vaccine-type and immunity on the burden of COVID-19.
    Taboe HB; Asare-Baah M; Iboi EA; Ngonghala CN
    Math Biosci; 2023 Jun; 360():108981. PubMed ID: 36803672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 elicits non-sterilizing immunity and evades vaccine-induced immunity: implications for future vaccination strategies.
    Beukenhorst AL; Koch CM; Hadjichrysanthou C; Alter G; de Wolf F; Anderson RM; Goudsmit J
    Eur J Epidemiol; 2023 Mar; 38(3):237-242. PubMed ID: 36738380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact and Effectiveness of COVID-19 Vaccines Based on Machine Learning Analysis of a Time Series: A Population-Based Study.
    Garcia-Carretero R; Ordoñez-Garcia M; Vazquez-Gomez O; Rodriguez-Maya B; Gil-Prieto R; Gil-de-Miguel A
    J Clin Med; 2024 Oct; 13(19):. PubMed ID: 39407950
    [No Abstract]   [Full Text] [Related]  

  • 18. Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET).
    Body A; Ahern E; Lal L; Gillett K; Abdulla H; Opat S; O'Brien T; Downie P; Turville S; Munier CML; Smith C; MacIntyre CR; Segelov E
    BMC Infect Dis; 2022 Jan; 22(1):70. PubMed ID: 35057745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Technical guidelines for seasonal influenza vaccination in China (2021-2022)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) , Influenza Vaccination TWG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Oct; 42(10):1722-1749. PubMed ID: 34814607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.